Journal Watch · Annals of the Rheumatic Diseases · 2026
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review.
Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.
TL;DR
Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.
Key findings
- Repeated renal biopsies showed no B-cell infiltration, but dominant chronic changes and podocytopathies post-CAR-T therapy.
- A mini-review demonstrated that the renal complete response rate of CAR-T therapy was 72.4%, and advanced age was associated with suboptimal response.
- Single-cell analysis confirmed B-cell reconstitution in 3/6 patients.<h4>Conclusions</h4>IM19 CAR T-cell therapy demonstrated a favourable safety profile and clinically meaningful systemic improvement.
- Responses to CAR-T therapy in LN were variable.
- Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
A literature search on the efficacy of CAR T-cell therapy in LN in PubMed database was conducted.<h4>Results</h4>Six patients with refractory SLE and renal involvement were enrolled. IM19 therapy was well tolerant, with mild cytokine release syndrome occurring in 4 patients. The median Systemic Lupus Erythematosus Disease Activity Index-2000 score decreased from 12 (range, 10-24) to 4 (range, 2-8) at day 90, and remained stable at 5 (range, 2-6) at day 180. The renal responses were heterogeneous with 2 complete responders, 2 partial responders, and 2 nonresponders.
Full abstract (original)
Background: <h4>Objectives</h4>This study aims to evaluate the efficacy and safety of IM19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell, in patients with refractory systemic lupus erythematosus (SLE), with a particular focus on lupus nephritis (LN).<h4>Methods</h4>This is an open-label, single-arm clinical trial. IM19 was administered following lymphodepletion. Repeated renal biopsies were performed at day 180. Single-cell RNA sequencing on peripheral blood mononuclear cells was performed pre- and 180-day post-CAR-T infusion.
What they did: A literature search on the efficacy of CAR T-cell therapy in LN in PubMed database was conducted.<h4>Results</h4>Six patients with refractory SLE and renal involvement were enrolled. IM19 therapy was well tolerant, with mild cytokine release syndrome occurring in 4 patients. The median Systemic Lupus Erythematosus Disease Activity Index-2000 score decreased from 12 (range, 10-24) to 4 (range, 2-8) at day 90, and remained stable at 5 (range, 2-6) at day 180. The renal responses were heterogeneous with 2 complete responders, 2 partial responders, and 2 nonresponders.
Results & conclusions: Repeated renal biopsies showed no B-cell infiltration, but dominant chronic changes and podocytopathies post-CAR-T therapy. A mini-review demonstrated that the renal complete response rate of CAR-T therapy was 72.4%, and advanced age was associated with suboptimal response. Single-cell analysis confirmed B-cell reconstitution in 3/6 patients.<h4>Conclusions</h4>IM19 CAR T-cell therapy demonstrated a favourable safety profile and clinically meaningful systemic improvement. Responses to CAR-T therapy in LN were variable. Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.
Abstract © the authors / Annals of the Rheumatic Diseases (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.ard.2025.12.014 · PubMed 41644365.
Why it matters for pharma & biotech
- Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: cell therapy (CAR-T / engineered cells)
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
Frequently asked questions
What did this Annals of the Rheumatic Diseases study find?
Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.
What type of study is this?
It is a review / perspective, published in Annals of the Rheumatic Diseases in 2026. A literature search on the efficacy of CAR T-cell therapy in LN in PubMed database was conducted.<h4>Results</h4>Six patients with refractory SLE and renal involvement were enrolled.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.ard.2025.12.014. PubMed ID: 41644365. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/heterogeneous-responses-of-im19-anti-cd19-car-t-cell-therapy-in-refracto-512014/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides